This week, a condition affecting roughly 1 in 8 women worldwide got a new name.
Polycystic Ovary Syndrome (PCOS) is now officially being renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The change, published in The Lancet on 12 May 2026 and endorsed by the Endocrine Society, followed a global consensus process involving researchers and clinicians across multiple specialties.
If you've been diagnosed with PCOS, or suspect you might have it, this matters. Not just as a semantic update, but because the new name reflects a better understanding of what the condition actually is.
Why the Name Changed
The old name was misleading in two ways. First, "polycystic" implied that having ovarian cysts was central to the condition. However, many women with PCOS never develop cysts, and the presence of cysts alone doesn't indicate PCOS. The term created diagnostic confusion and, according to the researchers behind the rename, contributed to delays in diagnosis and fragmented care.
Second, "syndrome" underplayed what the condition actually involves. PMOS is now understood to be a polyendocrine (affecting multiple hormone-producing systems) and metabolic condition, not primarily a reproductive or gynaecological one. Insulin resistance is central to most presentations, so are disruptions to androgen levels, cortisol, and in many cases, thyroid function.
The new name doesn't change the condition. It changes how clearly medicine frames what was already happening.
What PMOS Actually Is
At its core, PMOS is a condition driven by hormonal dysregulation, primarily involving insulin and androgens. Around 70% of people with PMOS have some degree of insulin resistance, meaning their cells are less responsive to insulin's signal, so the body produces more of it. Elevated insulin then stimulates the ovaries to produce excess androgens (male hormones like testosterone), which disrupts ovulation and menstrual regularity.
This is why the endocrine and metabolic framing is more accurate. The ovarian effects are real, but they're downstream of a hormonal and metabolic picture that's broader than the old name suggested.
Symptoms vary widely between individuals: irregular or absent periods, elevated androgens (acne, excess hair growth, hair thinning), difficulty losing weight, fatigue, and mood disturbance are among the most common. Diagnosis requires meeting specific clinical criteria; not everyone presents the same way.
What Nutrition Has to Do With It
The 2023 International Evidence-based Guidelines for PMOS management are clear on this: lifestyle modification, including dietary change, is first-line therapy. Not an adjunct. Not a nice-to-have. The first intervention.
Specifically, the evidence supports:
A Mediterranean-style or low glycaemic index (GI) diet. Both have demonstrated favourable effects on metabolic, reproductive, and hormonal markers in PCOS/PMOS. Low-GI eating reduces the insulin spikes that drive the androgen excess at the centre of the condition. The Mediterranean approach (whole foods, olive oil, fish, legumes, vegetables) reduces systemic inflammation that compounds hormonal disruption.
Limiting simple sugars and highly processed foods. These drive rapid insulin elevation, exactly the mechanism the condition is already predisposed to. This isn't about calorie restriction for its own sake. It's about reducing glycaemic load and the insulin response.
Prioritising prebiotic and gut-supporting foods. Gut microbiome disruption is increasingly recognised as a feature of PCOS/PMOS, not just a side effect. Fibre-rich foods and fermented foods support microbiome diversity in ways that appear to influence hormonal processing.
The Supplement Connection
Two nutrients deserve specific attention in the PMOS context:
Vitamin D. Deficiency is exceptionally common in women with PMOS. Studies suggest 67-85% have inadequate vitamin D levels, significantly higher than the already-high rate in the general Australian population. Vitamin D receptors are found in ovarian tissue. Deficiency is associated with worse insulin resistance, disrupted menstrual cycles, and elevated inflammatory markers, all of which worsen PMOS presentations. Correcting deficiency, ideally with D3 and K2 paired together, addresses multiple pathways simultaneously.
Magnesium. Lower serum magnesium is consistently found in women with PMOS compared to those without it. This is linked to the insulin resistance picture; magnesium plays a critical role in insulin signalling at the cellular level. Adequate magnesium improves insulin sensitivity, supports cortisol regulation (often disrupted in PMOS), and, particularly in the glycinate form, supports the sleep quality that tends to suffer with hormonal dysregulation. Research also suggests magnesium may have a modest effect on androgen levels.
Myo-inositol (a naturally occurring compound, not a vitamin) has some of the strongest evidence specific to PCOS/PMOS, particularly for improving insulin sensitivity, supporting ovulatory function, and reducing androgen levels. It falls outside RYSA's current product focus but is worth knowing about if you're researching the condition specifically.
What This Means Practically
A PMOS diagnosis isn't a life sentence. The condition is manageable, and dietary change is one of the most effective levers available, particularly when it's addressed early and consistently.
The rename to PMOS is helpful because it directs attention toward the endocrine and metabolic picture rather than the reproductive symptoms, which are often how the condition first gets noticed. Treating the metabolic root (insulin resistance, nutrient deficiencies, inflammation) addresses the downstream hormonal effects more effectively than treating symptoms in isolation.
If you've been diagnosed with PCOS and want to understand what that means for your nutrition specifically, a conversation with a nutrition practitioner who understands the evidence is worth having. The condition varies significantly between individuals, and a targeted approach based on your actual presentation will always outperform a generic one.